title: Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
abstract: There have been a number of recent advances in the treatment of patients with relapsed and refractory multiple myeloma. However, despite additional FDA-approved therapies including carfilzomib and pomalidomide as well as clinical trials investigating new combinations of existing treatments, multiple myeloma remains an incurable disease. New therapies currently in the drug development pipeline for relapsed and refractory disease include additional proteasome inhibitors (oprozomib, marizomib, ixazomib), histone deacetylase inhibitors (panobinostat, ricolinostat, quisinostat), monoclonal antibodies (daratumumab, elotuzumab, SAR650984), Bruton's tyrosine kinase inhibitors (ibrutinib), a selective inhibitor of nuclear export, and others. This review will focus on these newly developing therapies as well as the ever expanding role of the pharmacist in supportive care for patients with relapsed and refractory multiple myeloma.
authors.affiliation: University of Michigan Health System, Department of Pharmacy Services, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
authors.forename: Emily
authors.initials: E
authors.lastname: Ashjian
authors.affiliation: University of Michigan Health System, Department of Pharmacy Services, University of Michigan College of Pharmacy, Ann Arbor, MI, USA kredic@med.umich.edu.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Redic
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D056572:Histone Deacetylase Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000188:drug therapy*; D010595:Pharmacists / Q000639:trends; D024382:Professional Role; D061988:Proteasome Inhibitors / Q000627:therapeutic use*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D007155:Immunologic Factors; D061988:Proteasome Inhibitors; D013792:Thalidomide; C467566:pomalidomide
keywords: Multiple myeloma; investigational drugs; pharmacy; refractory; relapsed; supportive care